Navigation Links
Aspreva to be Acquired by Galenica For US$915 Million

- All-Cash Transaction Valued at US$26.00 Per Share -

VICTORIA, Oct. 17 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV) today announced that it has entered into a combination agreement with Galenica Group (SWX: GALN) under which Galenica, through a wholly-owned Canadian subsidiary, will acquire all of Aspreva's outstanding shares at a price of US$26.00 per share in cash. The total value of the transaction is approximately US$915 million.

This all-cash transaction for 100 per cent of the company's shares represents a 16 per cent premium over Aspreva's closing price on October 16th, 2007 and a 24 per cent premium over the 30-day average trading price of Aspreva shares.

Aspreva will host a conference call on October 18th, 2007, at 10:00 a.m. PT/ 1:00 p.m. ET to discuss the proposed acquisition.

The transaction was unanimously approved by Aspreva's Board of Directors on October 17th, following receipt of the recommendation of a Special Committee of the Board. Aspreva's Board has also resolved to recommend to shareholders that they vote in favor of the transaction. In determining to recommend the transaction to Aspreva shareholders, the Board of Directors considered a number of factors and received opinions from the company's financial advisors, Lazard and Lehman Brothers Inc., to the effect, and subject to the assumptions and conditions set forth in such opinions, that the consideration to be received by the holders of Aspreva common shares in the transaction is fair to such holders from a financial point of view.

About the Transaction

The transaction will be carried out by way of a statutory plan of arrangement under Section 288 of the British Columbia Business Corporations Act, and must be approved by the applicable court and by 66 2/3 per cent of the votes cast by holders of Aspreva shares. The completion of the transaction is also subject to customary closing conditions, including regulatory approvals. The transaction is expected to close on January 3rd, 2008, shortly after receipt of shareholder and court approvals.

Details regarding these and other terms of the transaction are set out in the Combination Agreement, which will be filed by Aspreva on the Canadian SEDAR website at and on the U.S. Securities and Exchange Commission's website at Further information regarding the transaction will be contained in a proxy circular that Aspreva will mail to holders of common shares in connection with the special meeting of shareholders to be held to approve the transaction. It is expected that these materials will be mailed in November 2007 for a meeting to be held in December 2007. Once mailed, the proxy circular will be available at and All shareholders are urged to read the proxy circular once it is available.

Shareholder Support Agreements

Aspreva's directors and officers, as well as Aspreva's largest shareholder, who collectively hold approximately 30 per cent of the outstanding common shares of Aspreva, have entered into agreements with Galenica to vote their shares in favor of the transaction, subject to their ability to withdraw such support in the event that the Combination Agreement is terminated, including where an unsolicited superior competing proposal is made by another bidder and accepted by Aspreva.

Financial and Legal Advisors

Lazard and Lehman Brothers Inc. are acting as financial advisors to Aspreva with respect to the arrangement. Aspreva's Canadian legal advisors are McCarthy Tetrault LLP, its US legal advisors are Cooley Godward Kronish LLP and its corporate counsel Farris, Vaughan, Wills & Murphy LLP.

Conference Call

Aspreva will host a conference call on Thursday, October 18, 2007 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time).

Dial-in information:

North America (toll free): 1-800-591-6942

International: 1-617-614-4909

Enter passcode: 42424615

The call will be available for replay until Thursday, October 26th, by calling 1-888-286-8010 (North America) or 1-617-801-6888 (International) and entering the pass code 63308627.

A live webcast will also be available to all interested parties on Aspreva's website: Please click on the "Webcasts and Events" link under the Investors section. A replay of the webcast will be available until January 19, 2008.

About Galenica

Galenica is a diversified group, active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical services and access to databases and sets up networks. The Galenica Group enjoys a leading position in all its areas of activity - pharmaceutical manufacturing, pre-wholesaling, distribution, healthcare information and retailing. A large part of the Group's income is generated by international operations. For more information please visit

About Aspreva

Aspreva is a global pharmaceutical company focused on identifying, developing, and, upon approval, commercializing evidence-based medicines for patients living with less common diseases. Aspreva common stock is traded on the NASDAQ Global Select Market under the trading symbol ASPV and on the Toronto Stock Exchange under the trading symbol ASV. Learn more about the company at

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of applicable securities laws in Canada (collectively, "forward-looking statements"). The words "anticipates", "believes", "budgets", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "projects", "schedule", "should", "will", "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this news release include, but are not limited to, statements about: the potential acquisition of Aspreva by Galenica in an all cash transaction valued at USD$26.00 per outstanding share (the "Acquisition"); a special meeting of Aspreva's shareholders to consider the Acquisition, currently scheduled for December 2007; and the approval of the Acquisition by Aspreva's shareholders and the Canadian regulatory authorities.

With respect to the forward-looking statements contained in this news release, Aspreva has made numerous assumptions regarding, among other things: Galenica's ability to finance the Acquisition valued at USD$26.00 per outstanding share; the ability of Aspreva and Galenica to satisfy all of the closing conditions to complete the Acquisition; Aspreva's ability to protect its intellectual property rights and to not infringe on the intellectual property rights of others; and Aspreva's ability to comply with applicable governmental regulations and standards. Readers are cautioned that the plans, intentions or expectations disclosed in any forward-looking statements and underlying assumptions may not be achieved and that they should not place undue reliance on any forward-looking statement. Actual results or events could differ materially from the plans, intentions, expectations, and assumptions expressed or implied in any forward-looking statements as a result of numerous risks, uncertainties and other factors, including those relating to: the possibility of not satisfying all of the closing conditions to complete the Acquisition; the possibility that Aspreva's shareholders do not approve the Acquisition at the special meeting of shareholders; risks related to integration of acquisitions; difficulties or delays in obtaining regulatory approvals; competition from other pharmaceutical or biotechnology companies; economic and capital market conditions; and currency exchange rates.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed with the U.S. Securities and Exchange Commission at and with securities regulatory authorities in Canada at Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of new information, future events or otherwise after the date hereof.

CONTACT: Sage J. Baker, Vice President, IR & Corporate Communications, Aspreva Pharmaceuticals, (250) 708-4270,

SOURCE Aspreva Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Reducing The Rate Of Hospital Acquired Infections
2. Hospital-acquired HIV Kills One Child in Kerala
3. Three Teslas magnetic resonance imager acquired. Shot in the arm for research
4. Drug May Make Breathing Easier for Millions
5. Hundred million dollar gift for malaria institute
6. George Bush pledges 200 million dollars for AIDS relief
7. Hope for 11 million children facing death from illnesses
8. The forgotten epidemic killing millions
9. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
10. Over Six Million HIV Infected People In South Africa- Finds A Survey
11. Tanzanian Government Sanctions $20 Million For AIDS Arug
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... Until now, the St. Louis Fetal Care Institute ... of Myelomeningocele Study) trial. One of these exclusion criteria was a BMI above 34.9. ... to 24.9 is considered normal, 25 - 29.9 is overweight and above 30 is ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a world ... announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking and ... platform which uses temperature as a clinical endpoint. The technology has been ...
(Date:11/30/2015)... ... November 30, 2015 , ... The world of hair transplants and restoration is ... These techniques and procedures have been in use for many years and are among ... Parsa Mohebi, M.D. has utilized many of these methods over the years, he also ...
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally ... styling. So why is it a national news story when Donald Trump makes disparaging ... M.D., because appearances count more than anyone wants to admit when it comes to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips  (NYSE: PHG ... Radiology Solutions, a fully integrated, consultative approach to ... data-driven practice management approaches that combine imaging systems, ... improve care delivery and reduce costs. Making its ... North America Annual Meeting (RSNA) in ...
(Date:11/30/2015)... -- global cell culture market is expected to ... by 2022 at a CAGR of 7.1% therein. --> ... 2013 value of US$6.1 bn to US$11.3 bn by 2022 at ... has announced the release of a new market research study, detailing ... Culture Market - Global Industry Analysis, Size, Share, Growth, Trends and ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
Breaking Medicine Technology: